TY  - JOUR
AU  - Colhoun, Helen M
AU  - Leiter, Lawrence A
AU  - Müller-Wieland, Dirk
AU  - Cariou, Bertrand
AU  - Ray, Kausik K
AU  - Tinahones, Francisco J
AU  - Domenger, Catherine
AU  - Letierce, Alexia
AU  - Israel, Marc
AU  - Samuel, Rita
AU  - Del Prato, Stefano
PY  - 2020
DO  - 10.1186/s12933-020-0991-1
UR  - http://hdl.handle.net/10668/15076
T2  - Cardiovascular diabetology
AB  - Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased cardiovascular risk. Non-HDL-C and...
LA  - en
KW  - Alirocumab
KW  - DM-DYSLIPIDEMIA
KW  - Diabetes mellitus
KW  - HDL-C
KW  - Non-HDL-C
KW  - ODYSSEY
KW  - PCSK9
KW  - Triglycerides
KW  - Type 2 diabetes
KW  - Usual care
KW  - Aged
KW  - Antibodies, Monoclonal, Humanized
KW  - Anticholesteremic Agents
KW  - Biomarkers
KW  - Cholesterol, HDL
KW  - Diabetes Mellitus, Type 2
KW  - Dyslipidemias
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - PCSK9 Inhibitors
KW  - Protease Inhibitors
KW  - Time Factors
KW  - Treatment Outcome
KW  - Triglycerides
TI  - Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.
TY  - research article
VL  - 19
ER  -